Von Willebrand Disease (VWD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by phenotypic forms as follows:
• Type 1: An autosomal dominant disease caused by a partial quantitative deficiency of von Willebrand factor (VWF), with incomplete penetrance at around 60%.
• Type 2: An autosomal dominant disease with several qualitative defects in VWF. It has four subtypes (2A, 2B, 2N, 2M), with 2A being the most common variant.
• Type 3: An autosomal recessive disease caused by a complete quantitative defect in VWF, resulting in undetectable levels and severe bleeding.
The VWF gene’s polymorphic nature leads to various VWF levels and functions, resulting in varying disease presentations and severity. Common symptoms of VWD include frequent nosebleeds lasting over 10 minutes, prolonged bleeding from cuts or injuries, easy bruising, iron deficiency anemia, excessive bleeding after surgeries (including dental), a family history of similar symptoms, or a diagnosed bleeding disorder. Acquired von Willebrand disease occurs due to secondary processes affecting VWF function. Associated conditions include various cancers, autoimmune disorders, metabolic disorders, drug side effects, and high-flow states in the vascular system. Diagnosis relies on lab tests measuring VWF and FVIII levels, with additional tests to determine VWD type. Distinguishing acquired von Willebrand syndrome from inherited VWD can be challenging. Blood group O individuals may have slightly lower VWF levels, complicating diagnosis. Standard VWD therapy involves replacing the deficient VWF protein. Treatment options include non-replacement therapy, replacement therapy using plasma-derived concentrates like Humate-P® and Alphanate SD/HT®, and antifibrinolytics like aminocaproic acid and tranexamic acid, which inhibit fibrinolysis.
• The prevalence of VWD in the general population ranges from 0.6% to 1.3%, but symptomatic VWD requiring specific treatment is rare (approximately 1 in 10,000). Type 3 VWD is rare, occurring in approximately 1 in 1,000,000 individuals.

Thelansis’s “Von Willebrand Disease (VWD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Von Willebrand Disease (VWD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Von Willebrand Disease (VWD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Von Willebrand Disease (VWD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Von Willebrand Disease (VWD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Von Willebrand Disease (VWD), Von Willebrand Disease (VWD) market outlook, Von Willebrand Disease (VWD) competitive landscape, Von Willebrand Disease (VWD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)